Phaseline

Companies › Miltenyi Biomedicine

Miltenyi Biomedicine: clinical trials, targets and expected readouts

4 active drug programs in 12 registered trials: 8 Phase 1, 4 Phase 2; Oncology, Immunology, Neurology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
zamtocabtagene autoleucel (MB-CART2019.1)
CD19-directed CAR-T cell therapy
CD19Phase 2Refractory Diffuse Large B Cell Lymphoma (DLBCL); DLBCL - Diffuse Large B Cell Lymphoma; B-Cell Neoplasm; Diffuse Large B-cell Lymphoma …Dec 2026
MB-CART19.1
Anti-CD19 CAR T cell therapy
CD19Phase 1Acute Lymphoblastic Leukemia Recurrent; SLE - Systemic Lupus ErythematosusNov 2026
MB-dNPM1-TCR.1
T cell receptor (TCR) therapy targeting dNPM1 peptide epitopes restricted to HLA A*02:01
NPM1Phase 1Leukemia, Myeloid, AcuteJun 2028
anti-CD19 CAR T cell therapy
anti-CD19 CAR-T cell therapy
CD19Phase 1Systemic Lupus Erythematosus; Relapse/Refractory B-cell Acute Lymphoblastic Leukemia; Systemic Lupus Erthematosus–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06347718anti-CD19 CAR T cell therapyPhase 1Systemic Lupus ErythematosusImmunologyMay 2026
NCT03853616MB-CART19.1Phase 1Acute Lymphoblastic Leukemia RecurrentOncologyNov 2026
NCT04792489zamtocabtagene autoleucel (MB-CART2019.1)Phase 2Refractory Diffuse Large B Cell Lymphoma (DLBCL)OncologyDec 2026
NCT07288879zamtocabtagene autoleucel (MB-CART2019.1)Phase 2DLBCL - Diffuse Large B Cell LymphomaOncologyJan 2027
NCT06635330anti-CD19 CAR T cell therapyPhase 1Relapse/Refractory B-cell Acute Lymphoblastic LeukemiaOncologySep 2027
NCT06189157MB-CART19.1Phase 1SLE - Systemic Lupus ErythematosusImmunologySep 2027
NCT06828042anti-CD19 CAR T cell therapyPhase 1Systemic Lupus ErthematosusImmunologyDec 2027
NCT06708845zamtocabtagene autoleucel (MB-CART2019.1)Phase 1Lupus NephritisImmunologyJan 2028
NCT06424340MB-dNPM1-TCR.1Phase 1Leukemia, Myeloid, AcuteOncologyJun 2028
NCT06508931zamtocabtagene autoleucel (MB-CART2019.1)Phase 2B-Cell NeoplasmOncologyDec 2029
NCT07178431zamtocabtagene autoleucel (MB-CART2019.1)Phase 1Multiple SclerosisNeurologyAug 2030
NCT04844866zamtocabtagene autoleucel (MB-CART2019.1)Phase 2Diffuse Large B-cell LymphomaOncologySep 2031

Targets

CD19 (3) NPM1 (1)

Companies with the same targets

Gilead Sciences Bristol-Myers Squibb Chongqing Precision Biotech Allogene Therapeutics Amgen AstraZeneca Beijing Yongtai Ruike Biotechnology Company Shanghai Ming Ju Biotechnology iCell Gene Therapeutics Novartis

Companies built like this

Grit Biotechnology Fate Therapeutics Shanghai Ming Ju Biotechnology PersonGen BioTherapeutics (Suzhou) Beijing Yongtai Ruike Biotechnology Company

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.